PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30012495-10	2018	In our studies, myricetin-induced increment of ALP activity was decreased by ERK (PD98059), JNK (SP600125), p38 (SB203580), and Smad 1/5/9 (LDN193189) inhibitors.	pyrazolanthrone	97-105	alkaline phosphatase, placental	Homo sapiens	47-50	
28833827-14	2017	Furthermore, inhibition of JNK by its inhibitor SP600125 dramatically blocked POSTN-enhanced scratch closure, ALP activity and mineralization in PDLSCs.	pyrazolanthrone	48-56	alkaline phosphatase, placental	Homo sapiens	110-113	
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	alkaline phosphatase, placental	Homo sapiens	312-332	
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	alkaline phosphatase, placental	Homo sapiens	334-337	
23657597-6	2013	Among the periosteal-derived cells pretreated with MAPK inhibitors, the ALP activity was markedly decreased in the cells pretreated with SP 600125, the specific inhibitor of C-Jun N-terminal kinase (JNK).	pyrazolanthrone	137-146	alkaline phosphatase, placental	Homo sapiens	72-75	
27959394-6	2017	The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs.	pyrazolanthrone	26-34	alkaline phosphatase, placental	Homo sapiens	125-128	
27484838-11	2016	Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs.	pyrazolanthrone	49-57	alkaline phosphatase, placental	Homo sapiens	145-148	
27106512-9	2016	The amentoflavone-induced increases of ALP and mineralization were significantly diminished when the JNK and p38 MAPK pathways were blocked by selected inhibitors (SP600125, SB203580) in hMSCs.	pyrazolanthrone	164-172	alkaline phosphatase, placental	Homo sapiens	39-42	
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	alkaline phosphatase, placental	Homo sapiens	32-35	
25994505-8	2015	In addition, addition of SP600125 or SB203580 also blocked apigenin-induced ALP activity, OPN, Runx2, and OSX expression and meanwhile inhibited bone nodule formation.	pyrazolanthrone	25-33	alkaline phosphatase, placental	Homo sapiens	76-79